11:40 AM EDT, 08/07/2025 (MT Newswires) -- Palisade Bio ( PALI ) shares were up 3% in recent Thursday trading after the company disclosed "positive" topline results from its phase 1b clinical study evaluating PALI-2108 in patients with ulcerative colitis.

The company said it recorded a 100% clinical response rate amongst its cohort of five patients with moderate-to-severe ulcerative colitis, a type of inflammatory bowel disease.

Separately, the company said it also completed a phase 1a study evaluating PALI-2108 for fibrostenotic Crohn's disease.

The company added that it plans to complete a phase 1b study by H2 2025.

Palisade Bio ( PALI ) also said that combined data from its previously completed phase 1a and 1b ulcerative colitis study and its planned fibrostenotic Crohn's trial will serve as the basis for a phase 2 investigational new drug application to the US Food and Drug Administration in H1 2026.

Price: 1.03, Change: +0.03, Percent Change: +3.00